Joshua Zeidner, Associate Professor of Medicine at the University of North Carolina at Chapel Hill, shared Daniel Peters’s, Assistant Professor at Georgia Cancer Center, post on X, adding:
“True privilege to be part of the MD Education AML ALL US Focus 2026 meeting! Always great to highlight the incredible advances of menin inhibitors and excited to discuss our upcoming RAVEN Study for newly diagnosed younger/fit KMT2Ar AML.”
Quoting Daniel Peters’s post:
“One of the many great talks at MD Education AML-ALL focus group. Joshua Zeidner of UNC Lineberger showing continued, impressive results of Menin-I in NPM1 and KMT2Ar AML and emphasis on frontline combos. Tip of the iceberg!”
Other articles featuring Dr. Zeidner and Dr. Peters on OncoDaily.
